Effects of plasmodium berghei infection on arteether metabolism and disposition

Pharmacology

Volumn 54, Issue 5, 1997, Pages 276-284

  Leo, Kathleen U ^a   Grace, James M ^a   Li, Qigui ^a   Peggins, Jim ^a   Mitchell, Alan L ^a   Aguilar, Tony ^a   Brewer, Thomas G ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

Antimalarials; Arteether; Cytochrome P450 (CAP450); Dihydroqinghaosu; Drug metabolism; Malaria

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; CYTOCHROME P450; DIHYDROARTEMISININ; DRUG METABOLIZING ENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME KINETICS; ISOLATED LIVER; MALARIA; MALE; MICROSOME; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HALF-LIFE; ISOTOPE LABELING; LIVER; MALARIA; MALE; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; PERFUSION; PLASMODIUM BERGHEI; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; TISSUE DISTRIBUTION;

EID: 0030740220     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139496     Document Type: Article

References (27)

1. Oaks SC, Mitchell VS. Pearson GW, Carpenter CCJ: Malaria: Obstacles and opportunities. A report of the Committee for the Study on Malaria Prevention and Control. Status Review and Alternative Strategies. Division of International Health. Institute of Medicine. Washington. National Academy Press, 1991.
2. Mien TT. White NJ: Qinghaosu. Lancet 1993:341:603-608.
3. Rosen S. Roycroft DW. Hans JE, Barry KG: The liver in malaria. Arch Pathol 1967:83:271-277.
4. Tekwani BL, Shukla OP. Ghatak S: Altered drug metabolism in parasitic diseases. Parasitol Today 1988:4: 4-9.
5. Alvares AP, Vcng TH, Schcibcl LW, Holingdalc MR: Impairment of hepatic cytochrome P450 dependent mono-oxygenases by malarial parasite Plasmodium berghei. Mol Bio-chem Parasitol 1984;13:277-282.
6. White NJ: Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacol 1985;10:187-215.
7. Kokwaro GO, Glazier AP. Ward SA, Breckenridge AM, Edwards G: Effect of malaria infection and endotoxin-induced fever on phenacc-tin O-dccthylation by rat liver microsomcs. Biochcm Pharmacol 1993;45:1235-1241.
8. Ismail S. Kokwaro GO, Back DJ. Edwards G: Effect of malaria infection on the pharmacokinetics of paracetamol in rat. Xcnobiotica 1994; 24:527-533.
9. Glazier AP. Kokwaro GO. Edwards G: Possible isozymc-spccific effects of experimental malaria infection wiht Plasmodium berghei on cytochrome P450 activity in rat liver mi-crosomes. J Pharnt Pharmacol 1994; 46:352-355.
10. Melendez V. Peggins JO. Brewer TG. Theoharides AD: Determination of the antimalarial artcelher and its deethylated metabolite dihydroartemisinin in plasma by high-performance liquid chromatography wit reductive electrochemical detection. J Pharnt Sci 1991:80:132-138.
11. Mihaly GW. Date NM. Ireton C. Smallwood RA: The effect of malaria infection on primaquine elimination in the isolated perfused rat liver. Biochcm Pharmacol 1987:36: 225-228.
12. Black RH, Ray AP: Experimental studies of the potentiation of pro-guanil and pyrimethamine by dap-sone using Plasmodium berghei in white mice. Am Trop Med Parasitol 1977;71:131-139.
13. Guengerich FP: Separation and purification of multiple forms of microsomal cytochrome P-450: Activities of different forms of cytochrome P-450 towards several compounds of environmental interest. J Biol Chem 1977;252:3970-3979.
14. Lowry OH. Rosebrough NJ. Farr AL. Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
15. Omura T, Sato RJ: The carbon-monoxide-binding pigment of liver microsomes. J Biol Chem 1964:239: 2370-2378.
16. Phillips AH. Langdon RG: Hepatic triphosphopyridine nucleotide-cytochrome c reductase: Isolation, characterization. and kinetic studies. J Biol Chem 1962:237:2652-2660.
17. Mihaly GW. Smallwood RA, Anderson JD, Jones DB. Webster LK. Vaj-da FJ: Hi receptor antagonists and hepatic drug disposition. Hepatology 1982;2:828-831.
18. Coleman MD. Mihaly GW. Ward SA, Edwards G, Howells RE. Breckenridge AM: The disposition of pyrimethamine in the isolated perfused rat liver. Biochem Pharmacol 1985; 34:2193-2197.
19. Gores GJ. Kosl LJ. LaRusso NF: The isolated perfused rat liver: Conceptual and practical considerations. Hepatology 1986:6:511-517.
20. Wolkoff AW, Johansen KL. Goeser T: The isolated perfused rat liver: Preparation and application. Anal Biochem 1987;167:1-14.
21. Holford N: MKMODEL Version 4. Ferguson, Biosoft, 1990.
22. Gibaldi M. Perrir D: Pharmacokinetics. ed. 2. New York, Marcel Dekker, 1982, pp 271-287.
23. Beal SL. Sheincr LB: NONMEM Users Guides. Part I-VIL San Francisco. University of California, 1992.
24. Grace JM. Peggins JO. Aguilar AJ, Brewer TG: Metabolism of arteether to dihydroquinghaosu by isozymes of human and rat sytochrome P-450. Am J Trop Med Hyg 1995:53: 280.
25. Coleman MD, Fleckcnstein L. Heif-fer MH: Primaquine disposition in the isolated perfused rat liver. Effect of mefloquine induced bile flow reduction. Biopharm Drug Dispos 1989:10:153-164.
26. Leo KU. Weschc DL. Marino MT. Brewer TG: Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. J Pharnt Pharmacol 1996;48:723-728.
27. Zimmerman HJ. Lewis JH: Drug-induced cholestasis. Med Toxicol 1987;2:112-160.